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Tandem duplications involving the BRAF kinase gene
have recently been identified as the most frequent genetic
alteration in sporadic pediatric glioma, creating a novel
fusion protein (f-BRAF) with increased BRAF activity. To
define the role of f-BRAF in gliomagenesis, we demon-
strate that f-BRAF regulates neural stem cell (NSC), but
not astrocyte, proliferation and is sufficient to induce
glioma-like lesions in mice. Moreover, f-BRAF-driven
NSC proliferation results from tuberin/Rheb-mediated
mammalian target of rapamycin (mTOR) hyperactivation,
leading to S6-kinase-dependent degradation of p27. Col-
lectively, these results establish mTOR pathway activa-
tion as a key growth regulatory mechanism common to
both sporadic and familial low-grade gliomas in children.
Supplemental material is available for this article.
Received July 10, 2012; revised version accepted October 10,
2012.
In the pediatric population, the most common solid
tumors originate in the brain, where they can be associated
with significant morbidity. Among the histological sub-
types, low-grade pilocytic astrocytomas (PAs) are the most
frequently encountered brain tumors (Central Brain Tu-
mor Registry of the United States 2012). PAs arise either
sporadically or in the context of the Neurofibromatosis
type 1 (NF1) inherited cancer disposition syndrome. Tu-
mors arising in children with NF1 typically develop along
the optic pathway, following biallelic inactivation of the
NF1 tumor suppressor gene in neuroglial cells. The NF1
protein (neurofibromin) is a negative regulator of the RAS
proto-oncogene such that neurofibromin loss in neuroglial
cells results in increased RAS-dependent mammalian
target of rapamycin (mTOR) signaling (Lee et al. 2010).
In contrast, sporadic PAs do not harbor mutations in the
NF1 gene (Kluwe et al. 2001) but rather are associated with
alterations in the BRAF gene locus (Pfister et al. 2008).
High-resolution genomic arrays and fluorescent in situ
hybridization (FISH) analysis have identified tandem dupli-
cations on chromosome 7q34 that create novel genes
containing thekinasedomainofBRAF fusedwith a fragment
of the KIAA1549 gene. Subsequent studies have confirmed
that the KIAA1549:BRAF fusion (f-BRAF) is found in 65%–
75% of sporadic PAs (Jones et al. 2008), leading to elevated
mitogen-activated protein kinase (MAPK) activation.
While it has been established that the presence of f-BRAF
is a hallmark of sporadic PAs with diagnostic potential, its
precise role in neuroglial cell growth and gliomagenesis is
unresolved. Although f-BRAF can transform NIH3T3 cells
(Jones et al. 2008), previous studies have demonstrated that
BRAF does not increase astrocyte proliferation (Jacob et al.
2009), induces senescence of astrocytes (Jacob et al. 2011)
and neural stem cells (NSCs) in vitro (Raabe et al. 2011),
and does not result in gliomagenesis when ectopically
expressed in mouse brains in vivo (Robinson et al. 2010).
In this study, we sought to define the role of this signature
genetic alteration in neuroglial cell function and glioma
formation. We demonstrate that f-BRAF regulates neuro-
glial cell growth in a cell type-specific manner via tuberous
sclerosis complex (TSC)/Rheb activation of mTOR and is
sufficient to induce glioma-like lesions in vivo.
Results and Discussion
The discovery of the signature KIAA1549:BRAF genetic
alteration represents a major advance in our understanding
of the molecular pathogenesis of sporadic PA. However,
subsequent studies have raised important questions re-
garding the role of this potential driver mutation in neu-
roglial cell proliferation and PA tumorigenesis. Moreover,
prior studies have examined the impact of wild-type or
oncogenic BRAF (BRAFV600E) expression on astrocyte or
astroglial progenitor function, rather than the signature PA-
associated BRAF fusion protein. To determine whether
f-BRAF expression is sufficient to confer a growth advan-
tage to neuroglial progenitor cells, we expressed f-BRAF in
cerebellar NSCs, since the majority of sporadic PAs arise in
the cerebellum (Ohgaki and Kleihues 2005). Primary NSC
cultures generated from postnatal day 1 (P1) mouse cere-
bella expressed the Sox2 stem cell and Olig2 glial pro-
genitor markers, but not glial fibrillary acidic protein
(GFAP; astrocyte) (Supplemental Fig. S1A), and were capa-
ble of multilineage differentiation (Supplemental Fig. S1B).
Cerebellar NSCs were transduced with either empty
pBABE-puro vector (pBABE) or f-BRAF. Since BRAF acti-
vates MAPK in aMEK-dependent manner, a constitutively
active MEK mutant (MEKQ56P; caMEK) was included. Fol-
lowing caMEK or f-BRAF expression in cerebellar NSCs,
there was increased MAPK activation (1.5-fold and twofold
increased Thr202/Tyr204 phosphorylation, respectively)
(Fig. 1A) and increased NSC proliferation, as assessed by
secondary neurosphere diameters (28% and 46% increases,
respectively), direct cell counting (1.5-fold increase) (Fig. 1B)
and limiting dilution analysis (37 6 7 pBABE-transduced
vs. 26 1 f-BRAF-transduced cells) (Supplemental Fig. S1C).
Oncogenic BRAF has been reported to induce activation
of the mTOR pathway in melanoma, thyroid, and breast
carcinomas (Babchia et al. 2010; Duong et al. 2012;
Faustino et al. 2012). In addition, previous studies
from our laboratory have demonstrated that the NF1
gene product neurofibromin regulates murine astrocyte,
NSC, and glioma growth in an mTOR-dependent manner
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(Dasgupta et al. 2005; Lee et al. 2010), raising the in-
triguing possibility that both NF1-associated and spo-
radic PA share mTOR pathway activation as a major
mitogenic driver. Consistent with this prediction, f-BRAF
expression in cerebellar NSCs resulted in increased phos-
phorylation (activation) of ribosomal S6 protein (5.8-fold
increase in Ser240/244, shown in Fig. 1C; 6.2-fold increase
in Ser235/236, shown in Supplemental Fig. S1D) and S6-
kinase (S6K) (Thr389 shown in Supplemental Fig. S1E).
Increased MAPK (1.6-fold) and S6 (1.7-fold) activation was
also observed following BRAFV600 expression in cerebellar
NSCs, with an accompanying increase in NSC prolifera-
tion (23% increase in neurosphere diameter and 1.5-fold
increase by direct cell counting) (Supplemental Fig. S1F).
We next sought to define how f-BRAF activates mTOR
signaling. First, similar to f-BRAF, caMEK expression in
NSCs resulted in S6 activation (Fig. 1C). Second, MEK in-
hibition with PD0325901 (PD901) reduced MAPK and S6
activation in both wild-type and f-BRAF-expressing NSCs
(Fig. 1D) but only inhibited the proliferation of f-BRAF-
expressing NSCs (Fig. 1 F,G). Third, rapamycin-mediated
mTOR inhibition attenuated the f-BRAF-induced in-
creases in S6 activation (Fig. 1E) and proliferation (Fig.
1F,G), similar to that observed following PD901 treatment.
Finally, whereas MEK inhibition blocked f-BRAF-induced
mTOR activation, rapamycin had no effect on f-BRAF-
induced MAPK activation (Supplemental Fig. S1G). Col-
lectively, these results demonstrate that f-BRAF regulates
NSC proliferation by activating the mTOR pathway in
a MEK-dependent manner.
Several studies have shown that ectopic expression of
either RAF or BRAF alone is not sufficient to induce
gliomas in mice (Lyustikman et al. 2008; Robinson et al.
2010; Gronych et al. 2011), suggesting that BRAF may not
be a driver mutation. However, BRAF expression was
targeted to progenitor cells in the cerebral hemispheres
rather than the more typical locations (cerebellum, optic
pathway, and brainstem) where f-BRAF-containing PAs
arise in children. To establish a causative role for the sig-
nature BRAF alteration in gliomagenesis, we show that
f-BRAF expression resulted in a fivefold increase in cere-
bellar NSC soft agar colony formation (Supplemental Fig.
S2A). Next, mCherry-expressing cerebellar NSCs infected
with control (pBABE) or f-BRAF were injected into the
cerebella of 3-wk-old wild-type mice and analyzed at 2.5
and 6 mo post-transplantation. At 2.5 mo, we observed
threefold increases in the numbers of Ki-67+ and Iba1+ cells
at the injection sites in mice transplanted with f-BRAF-
expressing NSCs (n = 3) relative to control virus-infected
NSCs (n = 3). In addition, there was only a modest increase
in cellularity and GFAP immunoreactivity and no nuclear
atypia or cells with piloidmorphologies (Supplemental Fig.
S2B,C). However, at 6 mo post-injection, mice trans-
planted with f-BRAF-expressing NSCs (n = 5) harbored
clear areas of increased cellularity near the injection sites,
consistent with glioma-like lesions, including abnormal
cell clusters with pale nuclei (Fig. 2A, H&E, inset), in-
creased GFAP+ cells with piloid morphologies and elon-
gated hair-like cytoplasmic processes (Fig. 2A, inset), in-
creased numbers of proliferating (Ki67+) cells (Fig. 2A,B),
increased microglial (Iba1+ cells) infiltration (Fig. 2A,B),
and increased numbers of endoglin+ endothelial cells (data
not shown) relative to pBABE-containing NSC-injected
control mice (n = 4). Whereas mCherry+ cells were identi-
fied at the injection sites from both pBABE- and f-BRAF-
transduced NSC-transplanted mice (Fig. 2A), both NSC-
derived astrocytes (GFAP and mCherry double-positive
cells) (Supplemental Fig. S2E) and host-derived astrocytes
(GFAP+ only) (Supplemental Fig. S2E) were detected in the
f-BRAF-expressing lesions. Consistent with the in vitro
results, there was also increased pMAPK and pS6 immu-
nostaining in f-BRAF-expressing NSC-engrafted mice at
both 2.5 and 6 mo of age (Fig. 2C; Supplemental Fig. S2D).
While no gross neurological deficits or changes in survival
were observed, body weight was reduced by 28% in mice
injected with f-BRAF-expressing NSCs.
The finding that f-BRAF expression in cerebellar NSCs
generated glioma-like lesions in the cerebellum following
engraftment likely reflects differences in the innate capabil-
ities of these brain region-specific NSCs. In this regard, pre-
vious studies from our laboratory have revealed NSC re-
gional specificity in response to f-BRAF expression and Nf1
gene loss. Whereas lateral ventricle NSCs exhibit marginal
or no increase in NSC proliferation following Nf1 inactiva-
tion or f-BRAF expression, respectively, third ventricle and
brainstem NSCs demonstrate increased proliferation and
Figure 1. f-BRAF expression induced NSC proliferation and mTOR
pathway activation. (A) Increased MAPK phosphorylation was ob-
served following caMEK and f-BRAF expression in cerebellar NSCs.
f-BRAF transgene expression was confirmed by RT–PCR. Increased
NSC proliferation (B) and S6 phosphorylation (C) were observed in
caMEK- and f-BRAF-expressing NSCs. S6 phosphorylation was atten-
uated following treatment with 2 nM PD0325901 (PD901) (D) and
0.2 nM rapamycin (Rap) (E). (F,G) PD901 and Rap restore f-BRAF-
expressing NSC proliferation to control (pBABE) levels. a-Tubulin
served as an internal loading control. (Veh) Vehicle. Error bars denote
mean 6 SD. Bars, 300 mm. (*) P < 0.05; (**) P < 0.01; (***) P < 0.001.
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gliogenesis (Lee et al. 2010, 2012). Consistent with prior
BRAF results (Raabe et al. 2011) and our recent findings
regarding NSC brain region heterogeneity (Lee et al. 2012),
no change in neocortex NSC proliferation was seen fol-
lowing f-BRAF expression (Supplemental Fig. S2F).
To determine whether sporadic human PAs likewise
exhibit increasedmTOR activation, we used a tissuemicro-
array (TMA) containing 54 sporadic PAs. Consistent with
the in vitro findings linkingMAPK andmTORactivation in
murine NSCs, a strong correlation was observed between
mTOR activation (pS6 immunostaining) and MAPK acti-
vation (pMAPK immunostaining; x2 test) (Supplemental
Fig. S2G). Since the BRAF genotyping was not available for
the PAs contained in the TMA, we analyzed 14 sporadic PA
cases in which the precise f-BRAF mutation was known
and found that all f-BRAF-containing PA tumors examined
had increased pMAPK and pS6 immunoreactivity relative
to normal brains (Fig. 2D; Supplemental Fig. S2H). In
addition, these tumors exhibited diffuse GFAP expression
and contained a smaller population of cells with Sox2
expression (Fig. 2D; Supplemental Fig. S2H).
To define the mechanism by which f-BRAF activates
mTOR in cerebellar NSCs, we performed several experi-
ments based on prior studies in other cell types, demon-
strating that MAPK can activate mTOR by several mech-
anisms, including 90-kDa ribosomal protein S6 kinase
(RSK) activation and inactivation of TSC protein function
(Ma et al. 2005; Carriere et al. 2008). First, we showed that
f-BRAF expression does not increase RSK phosphorylation
(Thr573), excluding RSK-mediated TORC1 activation as
the mechanism underlying f-BRAF growth regulation (Fig.
3A). Second, we observed a 2.6-fold increase in tuberin
phosphorylation (Ser939) following f-BRAF expression in
NSCs (Fig. 3A). Similarly, there was a 2.9-fold and 1.6-fold
increase in tuberin phosphorylation in NSCs after caMEK
and BRAFV600 expression, respectively (Supplemental Fig.
S3A,B). Moreover, treatment of f-BRAF-expressing NSCs
with PD901 reduced the observed increases in tuberin and
S6 phosphorylation (Fig. 3B), demonstrating that f-BRAF-
induced tuberin phosphorylation was MEK-dependent.
Since prior reports on BRAF growth regulation in
astrocytes have yielded conflicting results, we transduced
primary GFAP+ but Sox2/Olig2-negative astrocytes from
P1–P2 mouse cerebella (Supplemental Fig. S3C) with
pBABE, BRAFV600 or f-BRAF. Consistent with the known
effects of BRAF on MAPK activation, both BRAFV600 and
f-BRAF expression increased MAPK phosphorylation (6.5-
fold and 4.4-fold, respectively), but neither BRAF molecule
increased astrocyte proliferation (Fig. 3C). The inability of
BRAF to increase astrocyte proliferation was not the result
of induced cellular senescence or programmed cell death
(TUNEL labeling) (Supplemental Fig. S3D). Similarly, this
failure to increase cell proliferation was also observed in
another astrocyte population (forebrain) despite increased
MAPK activation (Supplemental Fig. S3E). Moreover, the
inability of BRAF to increase astrocyte proliferation was
not dependent on mitogen (EGF, PDGF, or PACAP) avail-
ability (Supplemental Fig. S3F). Consistent with the finding
that BRAF-inducedMAPK activation is dependent onMEK
activity (Supplemental Fig. S3G), caMEK expression also
did not increase primary astrocyte proliferation (Supple-
mental Fig. S3H). Together, these results demonstrate that
f-BRAF increases neuroglial cell proliferation in a cell type-
specific manner unrelated to its ability to activate MEK/
MAPK signaling. This observed cell type specificity un-
derscores the critical cellular context in which cancer-
associated driver mutations must occur in order to facili-
tate proliferation, transformation, and tumorigenesis. The
differential response of NSCs and astrocytes to f-BRAF
expression is consistent with previously reported roles for
neuroglial progenitors in gliomagenesis (Taylor et al. 2005;
Alcantara Llaguno et al. 2009; Liu et al. 2011).
To elucidate the mechanism underlying this cell type-
specific effect, we compared the status of mTOR pathway
activation following f-BRAF expression in astrocytes and
NSCs.While f-BRAF expression inNSCs resulted in an 8.6-
fold increase in S6 phosphorylation, there was no change in
S6 phosphorylation following f-BRAF expression in astro-
cytes (Fig. 3D). Furthermore, therewas no change in tuberin
phosphorylation following f-BRAF expression in astrocytes
(Fig. 3E), indicating that MAPK, although activated by
f-BRAF, was unable to phosphorylate and inactivate tuberin
and thus could not activate mTOR in astrocytes.
We next sought to define the potential mechanism un-
derlying differential tuberin phosphorylation in NSCs rela-
tive to astrocytes. Following hypotonic lysis fractionation,
there was;13-fold more tuberin in the membrane fraction
of astrocytes comparedwithNSCs following normalization
to total tuberin in each fraction (Fig. 3F). These results
support a model in which cell type-specific f-BRAF-medi-
ated mTOR activation reflects the subcellular localization
of tuberin. Polycystin-1, an integral membrane protein,
suppresses mTOR activation by directly interacting with
Figure 2. f-BRAF induced glioma-like lesions in mice, and mTOR
activation was observed in human PAs. (A) Injection sites (dotted
lines) contain mCherry+ pBABE- or f-BRAF-expressing cells. Abnor-
mal cell clusters with pale nuclei (insets, H&E), increased number of
GFAP-immunoreactive cells with piloid morphologies (inset), in-
creased Ki67+ cells (arrows and inset; see also B, top), and increased
Iba1+ cells (arrows and inset; see also B, bottom) were observed in
f-BRAF-induced lesions. (C) Increased numbers of pMAPK+ and pS6+
cells (arrows) were found in f-BRAF-induced lesions. (D) Represen-
tative images show increased pMAPK and pS6 staining, along with
increased GFAP and Sox2 immunoreactivity, in f-BRAF-containing
human PAs. A normal human brain was used as a reference control.
Error bars denote mean 6 SD. (*) P < 0.05; (**) P < 0.01. Bars, 50 mm.
BRAF regulation of neuroglial growth
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membrane-bound tuberin, preventing its phosphorylation
and subsequent inactivation (Distefano et al. 2009; Dere
et al. 2010). We found that cerebellar astrocytes express 20-
fold more polycystin-1 relative to their NSC counterparts
(Supplemental Fig. S3I), potentially implicating polycystin-1
in the regulation of tuberin subcellular localization in
astrocytes. However, shRNA-mediated polycystin-1 knock-
down in astrocytes did not alter tuberin localization inwild-
type astrocytes (Supplemental Fig. S3J), increase tuberin
phosphorylation, or increase f-BRAF-expressing astrocyte
proliferation (Supplemental Fig. S3K), excluding polycystin-1
as the molecular etiology responsible for the cell type-
specific effects of f-BRAF in astrocytes andNSCs. It is likely
that other mechanisms account for the differential sub-
cellular localization of tuberin relevant to its inactivation
by phosphorylation.
Tuberin phosphorylation leads to loss of tuberin/hamartin
complex inhibition of Rheb and subsequent increased Rheb-
mediated mTOR activation (Castro et al. 2003; Inoki
et al. 2003). We next sought to determine whether f-BRAF
regulates mTOR activation in a tuberin/Rheb-dependent
manner in NSCs. First, to confirm that TSC
complex inactivation was responsible for
f-BRAF-mediated mTOR activation, we
expressed f-BRAF in wild-type or Tsc1/
NSCs. Compared with their wild-type coun-
terparts, empty vector-expressing Tsc1/
NSCs exhibited a 2.5-fold increase in S6
phosphorylation as well as increased NSC
proliferation (1.5-fold increase in cell num-
ber and 23% increase in neurosphere di-
ameter). However, f-BRAF expression did
not further increase S6 phosphorylation or
proliferation in Tsc1/ NSCs (Fig. 4A,B).
Second, ectopic Rheb expression in NSCs
using a conditional Rheb-expressing mouse
strain (Banerjee et al. 2011) resulted in a 2.1-
fold increase in S6 activation (Supplemental
Fig. S4A) and increased NSC proliferation
(1.4-fold in cell number; 23% increase in
neurosphere diameter) (Supplemental Fig.
S4B). Third, to determine whether f-BRAF
regulation of mTOR required Rheb acti-
vation, Rheb expression was reduced by
shRNA-mediated knockdown. Attenuated
Rheb expression (70% reduction) using two
different shRNA constructs in f-BRAF-trans-
duced NSCs reduced S6 phosphorylation
and proliferation to wild-type levels with
no effect on wild-type NSCs (Fig. 4C,D;
Supplemental Fig. S4C). Together, these
results establishTSC/Rheb-mediatedmTOR
activation as the mechanism underlying
f-BRAF-mediated growth regulation of cere-
bellar NSCs.
Since mTOR can regulate cell growth in
either an mTORC1-dependent (4E-BP1 and
STAT3) or mTORC2-dependent (AKT) man-
ner, we examined the activation state of
each of these downstream signaling mole-
cules. No changes in 4E-BP1 (Thr37/46),
STAT3 (Ser727), or AKT (Ser473) were ob-
served following f-BRAF expression in cere-
bellar NSCs (data not shown). mTOR can
also regulate proliferation and cell cycle
progression by increasing p27 phosphorylation and reduc-
ing total p27 expression (Hong et al. 2008; Dalvai et al.
2010). Following f-BRAF expression, there was increased
p27 phosphorylation (Thr187) and decreased total p27
expression (Supplemental Fig. S4D). Moreover, both MEK
(PD901) and mTOR (rapamycin) inhibition reduced p27
phosphorylation and restored p27 protein expression to
wild-type levels (Supplemental Fig. S4D), indicating that
f-BRAF controls NSC proliferation via mTOR-dependent
regulation of p27 levels.
To elucidate the mechanism underlying f-BRAF regula-
tion of p27 expression in cerebellar NSCs, we examined the
mTOR downstream target S6K. Human S6K1 (hS6K1)
expression increased NSC proliferation as well as p27
phosphorylation and decreased p27 protein levels (Supple-
mental Fig. S4E,F). In addition, S6K1 knockdown using two
different shRNA constructs abrogated the f-BRAF-medi-
ated increase in cell proliferation, S6 activation, and p27
phosphorylation and restored p27 expression to wild-type
levels (Fig. 4E,F; Supplemental Fig. S4G). To assess whether
p27 phosphorylation required cyclin-dependent kinase
Figure 3. Cell type-specific effects of f-BRAF expression on NSC proliferation and
tuberin phosphorylation. (A) Increased tuberin phosphorylation was observed in f-BRAF-
expressing NSCs, with no change in RSK phosphorylation. (B) f-BRAF-induced tuberin and
S6 phosphorylation was inhibited by PD901 treatment. (C) Increased MAPK phosphory-
lation was observed in BRAFV600- and f-BRAF-expressing astrocytes. f-BRAF transgene
expression was verified by RT–PCR. Compared with the vector control, BRAF expression
did not increase astrocyte proliferation. (D) Increased S6 phosphorylation was observed in
f-BRAF-expressing NSCs but not astrocytes. (E) f-BRAF expression increased tuberin
phosphorylation in NSCs but not astrocytes. a-Tubulin served as an internal loading
control. (F) Increased tuberin membrane localization was observed in astrocytes compared
with NSCs. Calnexin served as a marker for the membrane fraction. (C) Cytosol; (M)
membrane; (Veh) vehicle. Error bars denote mean 6 SD. (NS) Not significant.
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2 (Cdk2) (Montagnoli et al. 1999), f-BRAF-expressing NSCs
were treated with the Cdk2 inhibitor purvalanol-A (PurA).
Following PurA treatment, f-BRAF-induced cerebellar NSC
proliferation (Supplemental Fig. S4H) and p27 phosphory-
lation were restored to wild-type levels with no effect on
mTOR activation (Fig. 4G). Collectively, these results es-
tablish that f-BRAF regulation of NSC proliferation re-
quires mTOR-mediated activation of S6K1 to suppress p27
levels in a Cdk2-dependent manner (Fig. 4H).
The finding that f-BRAF regulates NSC growth in an
mTOR-dependent manner establishes a central growth
control target for both sporadic (KIAA1549:BRAF) and
familial (NF1-associated) pediatric low-grade glioma and
provides compelling preclinical evidence for the use of
mTOR pathway inhibitors for these common
childhood cancers. It is worth noting that while
both f-BRAF activation and NF1 loss lead to
mTOR activation, the mechanism underlying
mTOR regulation in each case is distinct.
Whereas neurofibromin loss activates mTOR
and leads to TORC2-dependent AKTactivation,
resulting in p27 phosphorylation and degradation
(Lee et al. 2010), f-BRAF expression causes MEK-
dependent tuberin inactivation and Rheb-di-
rected TORC1/S6K-mediated p27 phosphoryla-
tion and degradation. These divergent mecha-
nisms underscore the innate heterogeneity at the
tissue (brain region), cellular (astrocyte/NSC), and
molecular levels relevant to gliomagenesis.
Materials and methods
Mice
Tsc1flox/floxmice (Uhlmann et al. 2002) and conditional Rheb-
expressing transgenic mice (Banerjee et al. 2011) were gener-
ated as previously described. All mice were maintained on
a C57BL/6 background and used in accordance with an
approved Animal Studies protocol atWashington University.
Human tumor samples
Tumor specimens were obtained from the Tissue Procure-
ment Core Facility at Washington University under an
approved Institutional Review Board protocol.
Primary astrocyte and NSC cultures
Cerebellar hemispheres were microdissected from the brains
of C57BL/6 mouse pups to establish primary astrocyte and
NSC cultures, and proliferation assays were performed as
previously described (Dasgupta and Gutmann 2005; Lee et al.
2010; Banerjee et al. 2011). Wild-type and Tsc1/NSCs were
generated fromTsc1flox/flox pups following infectionwith LacZ
and Cre adenovirus, respectively. Retroviral and lentiviral
(Supplemental Table 1) transduction was performed (Lee et al.
2010) for overexpression and knockdown studies, respectively.
Expression of the f-BRAF transgene was verified by RT–PCR
(Lee et al. 2012). All in vitro experiments were performed at
least three times using primary NSC and astrocyte cultures
generated using pups from different litters and were indepen-
dently transduced with the respective constructs.
Subcellular fractionation
Following hypotonic (10 mM HEPES at pH 7.9, 1.5 mM
MgCl2, 10mMKCl, protease inhibitors) lysis and disruption
of cells with a 30-gauge syringe needle, crude nuclei were
pelleted by centrifugation, and supernatants were subjected to ultracen-
trifugation at 100,000g for 1 h at 4°C to generate cytosolic and membrane
fractions. Equal percentages of each fraction were subjected to SDS-PAGE
and immunoblot analysis.
Western blotting
Cell lysis, SDS-PAGE, and immunoblot analysis were performed as
previously reported (Uhlmann et al. 2004).
Intracranial injections
Three-week-old wild-type C57/BL6 mice were anesthetized by an in-
traperitoneal (i.p.) injection of 100 mg/kg ketamine and 6 mg/kg xylazine.
NSCs (5 3 105) in 2 mL of PBS were injected into the cerebellum using
Figure 4. f-BRAF-induced NSC proliferation requires TSC/Rheb-mediated mTOR
activation of S6K. (A) Increased S6 phosphorylation was observed in Tsc1/ NSCs
expressing empty vector (pBABE). Additional increases in S6 phosphorylation were
not seen in f-BRAF-expressing Tsc1/ NSCs. (B) f-BRAF did not increase Tsc1/
NSC proliferation. Rheb knockdown (shRheb) inhibited f-BRAF-induced S6 phos-
phorylation (C) and NSC proliferation (D) to control levels. S6K1 knockdown
(shS6K1) inhibited the f-BRAF-dependent increase in S6 and p27 phosphorylation
(E) and NSC proliferation (F). (G) Treatment with 150 nM purvalanol-A (PurA)
inhibited f-BRAF-induced p27 phosphorylation and protein degradation without
affecting S6 activation. a-Tubulin served as an internal loading control. (H) Proposed
mechanism of f-BRAF NSC growth regulation. (Veh) Vehicle. Error bars denote
mean 6 SD. (*) P < 0.01; (**) P < 0.05; (NS) not significant.
BRAF regulation of neuroglial growth
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a Hamilton syringe 3 mm below the dura mater using a stereotaxic
apparatus. Mice were euthanized 2.5 and 6 mo later.
Immunostaining
Paraffin or frozen sections were processed (Dasgupta and Gutmann 2005)
prior to staining with appropriate antibodies (Supplemental Table 2).
Statistical analysis
All in vitro experiments were analyzed using the Student’s t-test.
Statistical significance was set at P < 0.05.
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